Results 101 to 110 of about 36,254 (205)

Effects of Verapamil and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban

Pharmaceutics, 2019
Concomitant use of rivaroxaban with non-dihydropyridine calcium channel blockers (non-DHPs) might lead to an increase of systemic rivaroxaban exposure and anticoagulant effects in relation to the inhibition of metabolic enzymes and/or transporters by non-
Minsoo Kim, Heebin Son, Keumhan Noh, Eunyoung Kim, Beom Soo Shin, Wonku Kang   +5 more
doaj   +1 more source

Impact of rivaroxaban on stent thrombosis and secondary prevention of cardiovascular events in acute coronary syndrome

, 2014
Marvin Krohn-Grimberghe, Christoph Bode, Constantin von zur MuhlenDepartment of Cardiology and Angiology I, Heart Center, University of Freiburg, GermanyAbstract: Angioplasty and stent implantation have greatly improved the outcome of patients with acute
Krohn-Grimberghe M, von zur Muhlen C, Bode C   +2 more
core  

Mass spectrometry parameters for rivaroxaban monitoring.

, 2017
Mass spectrometry parameters for rivaroxaban monitoring.
Claudio Ernesto Albers Mendes (3723241), Carlos Eduardo dos Santos Ferreira (3344150), Priscilla Bento Matos Derogis (3723232), Marcelo Katz (695963), Livia Rentas Sanches (3723250), Carolina Nunes França (386340), Valdir Fernandes de Aranda (3723244), Marjorie Paris Colombini (3723238), João Carlos de Campos Guerra (3723235), Cristóvão Luis Pitangueira Mangueira (3723253), Adriana Caschera Leme Faulhaber (3723247)   +10 more
core   +1 more source

Developing and Evaluating a Laboratory‐Based Frailty Index for the Prediction of Long‐Term Health Outcomes in Systemic Lupus Erythematosus

Arthritis Care &Research, Volume 78, Issue 11, Page 1593-1601, November 2026.
Objective We aimed to construct and evaluate the first laboratory‐based frailty index (FI‐Lab) for predicting adverse outcomes in systemic lupus erythematosus (SLE) and to compare its predictive ability to that of an existing clinical FI. Methods We used data from a single‐center prospective cohort of adult patients with SLE whose baseline visit ...
Grace Burns, Samuel D. Searle, Alexandra Legge   +2 more
wiley   +1 more source

Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study

Pharmaceuticals, 2012
Dual antiplatelet therapy with acetylsalicylic acid and a thienopyridine, such as clopidogrel, is effective for the secondary prevention of cardiovascular events in patients with acute coronary syndrome, but there is still a substantial residual risk of ...
Michael Becka, Wolfgang Mück, Stephan Schwers, Dagmar Kubitza   +3 more
doaj   +1 more source

A Model for Estimating the Risk of Gastrointestinal Bleeding for Patients on Oral Anticoagulants and Interacting Medications

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 11, November 2026.
ABSTRACT Introduction Pharmacodynamic drug–drug interactions (DDI) in patients receiving oral anticoagulants (OAC) may increase the risk of gastrointestinal bleeding (GIB). The purpose of this study was to develop and validate a GIB model for patients receiving OACs.
Ainhoa Gomez‐Lumbreras, Abdelrahman G. Tawfik, Thomas Reese, Daniel M. Witt, Guilherme Del Fiol, Daniel C. Malone   +5 more
wiley   +1 more source

A Case of Rivaroxaban Associated Intracranial Hemorrhage [PDF]

, 2014
Rivaroxaban is a newer anticoagulant initially approved by the Food and Drug Administration to treat nonvalvular atrial fibrillation. Rivaroxaban has several characteristics that are more favorable than warfarin.
Lo, Jean CY, Roy R. Gerona, Gerona, Roy R, Jean Chin-Yu Lo   +3 more
core   +1 more source

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Clinical Pharmacology: Advances and Applications, 2014
Charles Frost,1 Yan Song,1 Yu Chen Barrett,1 Jessie Wang,2 Janice Pursley,3 Rebecca A Boyd,4 Frank LaCreta1 1Exploratory Clinical and Translational Research, 2Exploratory Development Global Biometric Sciences, 3Analytical and Bioanalytical Development ...
Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F   +6 more
doaj  

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.

PLoS ONE
BackgroundThe European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice ...
Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez   +9 more
doaj   +1 more source

Inside the ‘Black Box’ of Pharmaceuticalisation: NICE, the Permissive Principle and the Case of Anticoagulants [PDF]

Sociol Health Illn
ABSTRACT Sociological interest in pharmaceuticalisation continues to grow, especially regarding the expansion of pharmaceutical use in society. This article presents the first major empirical study focusing on the directionality of pharmaceuticalisation by taking cost‐effectiveness assessment and regulation of anticoagulants in England by the National ...
Abraham J, Balendran G.
europepmc   +2 more sources